On December 20, 2021 Filtricine reported that the preclinical research results of its proprietary medical food technology, Targeted Nutrients Deprivation (TND), have been published in Nutrition and Cancer.
"Broad Anti-Cancer Activity Produced by Targeted Nutrients Deprivation (TND) of Multiple Non-Essential Amino Acids" (Press release, Filtricine, DEC 20, 2021, View Source [SID1234597472])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Filtricine’s core medical food technology is the deprivation of non-essential amino acids (NEAAs) to manage cancer. Cancer cells, but not normal cells, require those NEAAs due to their heightened and rewired metabolism. Mice fed TND medical food diet with implanted human-derived tumors showed marked reduction in tumor growth. In combination with chemotherapy and immunotherapy, TND diet enhanced the efficacy of tumor suppression. TND diet was entirely safe in mice.

Filtricine is developing a human version of the TND diet, Tality, as a medical food to manage cancer. Filtricine is sponsoring a clinical study at Stanford University School of Medicine for the use of Tality in the management of prostate cancer. Tality is available to prostate cancer patients through this trial. If you are interested in joining the trial, please contact the trial coordinator. Deirdre Crommie at 650-387-7797 or [email protected]

Tality is also available to all cancer patients for free through a volunteer study. Please contact [email protected] if you would like to know more.